Proteostasis Therapeutics Inc. (PTI)

3.11
0.18 6.10
NASDAQ : Health Technology
Prev Close 2.93
Open 2.92
Day Low/High 2.85 / 3.18
52 Wk Low/High 1.41 / 8.61
Volume 3.20M
Avg Volume 937.50K
Exchange NASDAQ
Shares Outstanding 36.08M
Market Cap 110.05M
EPS -2.30
Div & Yield N.A. (N.A)

Latest News

Proteostasis Announces Presentations At The 41st European Cystic Fibrosis Society Conference

Proteostasis Announces Presentations At The 41st European Cystic Fibrosis Society Conference

BOSTON, June 1, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by...

First Week Of PTI May 18th Options Trading

Investors in Proteostasis Therapeutics Inc saw new options begin trading this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTI options chain for the new May 18th contracts and identified the following put contract of particular interest.

Proteostasis Announces Formation Of Independent Steering Committee Of Leading Experts To Advise On The Global Phase 3 Clinical Development Program For PTI-428 In Cystic Fibrosis

Program to Pursue Broad Label for PTI-428 as an Add-On Therapy to CFTR Modulator Based Treatment

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Proteostasis Therapeutics, Inc. Investors (PTI)

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Proteostasis Therapeutics, Inc. Investors (PTI)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation For PTI-428 In Cystic Fibrosis

Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation For PTI-428 In Cystic Fibrosis

Designation granted for PTI-428 for the treatment of CF patients based on the results from a recent Phase 2, randomized, placebo controlled study

That Wild Market Momentum Has Cooled

That Wild Market Momentum Has Cooled

But here are some movers I am looking at today.

TheStreet Quant Rating: D (Sell)